Expression Profiling and MicroRNA Regulation of the LKB1 Pathway in Young and Aged Lung Adenocarcinoma Patients

Overview

Journal Biomed Rep

Specialty Biochemistry

Date 2018 Oct 2

PMID 30271594

Citations 3

Authors

Laura Boldrini

Mirella Giordano

Marco Lucchi

Franca Melfi

Gabriella Fontanini

Affiliations

Soon will be listed here.

Abstract

Lung cancer in young patients appears to have distinct clinicopathological features. The present study focused on the role of the serine/threonine kinase liver kinase B1 (), a known tumor suppressor gene, and its miRNA regulation in lung adenocarcinoma, particularly in young versus elderly patients. A total of 88 patients with lung adenocarcinoma were retrospectively analysed. A simultaneous quantification was performed of the expression of mRNA and 15 microRNAs (miRNA/miRs; miRs -93, -96, -34a, -34c, -214, -33a, -30b, -145, -182, -30c, -183, -29b, -29c, -153 and -138) involved in the LKB1 pathway, as well as of 5 identified target mRNAs [cyclin D1 (), catenin β-1 (), lysyl oxidase (), yes-associated protein 1 () and survivin], using NanoString technology. mutations were investigated by pyrosequencing analysis. Patients ≤50 years were defined as a younger group, while patients >50 years old as an older group (n=44/group). No difference between the two groups was identified in terms of survival times analysed using the Kaplan-Meier method or mutations. Subsequently, the LKB1 signalling pathway was focused on, as a target for therapy in lung adenocarcinoma, and assessed with regards to clinicopathological features; we found that levels in adenocarcinoma patients were significantly associated with histological subtype (P=0.03), stage (P<0.0001) and prognosis (P=0.02 for disease-free interval and P=0.005 for overall survival), but not with age. Furthermore, the miRNA target prediction model indicated that miR-93 and miR-30b appeared to have functional binding sites and downregulate the gene expression of and , respectively. In conclusion, young patients appeared have similar survival rates to elderly patients. The assessment of , its downstream genes and its regulation by miRNAs may have an impact on future research on lung adenocarcinoma in young and elderly patients. Further investigations will be necessary to elucidate the potential of this pathway as a novel target for therapy.

Citing Articles

Angiotensin-Converting Enzyme 2 Enhances Autophagy via the Consumption of miR-326 in a Mouse Model of Acute Lung Injury.

Lin X, Gao F Biochem Genet. 2025; .

PMID: 39869241 DOI: 10.1007/s10528-025-11040-3.

Insights into targeting LKB1 in tumorigenesis.

Trelford C, Shepherd T Genes Dis. 2024; 12(2):101402.

PMID: 39735555 PMC: 11681833. DOI: 10.1016/j.gendis.2024.101402.

Aging and cancer: Clinical role of tumor markers in the geriatric population (Review).

Sundaresan S, Rajapriya P, Lavanya S Med Int (Lond). 2024; 4(3):21.

PMID: 39640494 PMC: 11618985. DOI: 10.3892/mi.2024.145.

Expression of miRNA-25 in young and old lung adenocarcinoma.

Boldrini L, Giordano M, Melfi F, Lucchi M, Fontanini G J Res Med Sci. 2022; 26:132.

PMID: 35126595 PMC: 8772505. DOI: 10.4103/jrms.JRMS_830_19.

References

Geiss G, Bumgarner R, Birditt B, Dahl T, Dowidar N, Dunaway D . Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol. 2008; 26(3):317-25. DOI: 10.1038/nbt1385. View

Mairinger F, Walter R, Werner R, Christoph D, Ting S, Vollbrecht C . Activation of angiogenesis differs strongly between pulmonary carcinoids and neuroendocrine carinomas and is crucial for carcinoid tumourgenesis. J Cancer. 2014; 5(6):465-71. PMC: 4066358. DOI: 10.7150/jca.9235. View

Pan Y, Zhang Y, Li Y, Hu H, Wang L, Li H . ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features. Lung Cancer. 2014; 84(2):121-6. DOI: 10.1016/j.lungcan.2014.02.007. View

Jian S, Hsiao C, Chen S, Weng C, Kuo T, Wu D . Utilization of liquid chromatography mass spectrometry analyses to identify LKB1-APC interaction in modulating Wnt/β-catenin pathway of lung cancer cells. Mol Cancer Res. 2014; 12(4):622-35. DOI: 10.1158/1541-7786.MCR-13-0487. View

Kim L, Kim K, Yoon Y, Ryu J, Choi S, Park I . Clinicopathologic and molecular characteristics of lung adenocarcinoma arising in young patients. J Korean Med Sci. 2012; 27(9):1027-36. PMC: 3429819. DOI: 10.3346/jkms.2012.27.9.1027. View

Beckett P, Callister M, Tata L, Harrison R, Peake M, Stanley R . Clinical management of older people with non-small cell lung cancer in England. Thorax. 2012; 67(9):836-9. DOI: 10.1136/thoraxjnl-2011-200994. View

Lara M, Brunson A, Wun T, Tomlinson B, Qi L, Cress R . Predictors of survival for younger patients less than 50 years of age with non-small cell lung cancer (NSCLC): a California Cancer Registry analysis. Lung Cancer. 2014; 85(2):264-9. DOI: 10.1016/j.lungcan.2014.04.007. View

Kuo C, Chen Y, Chao J, Tsai C, Perng R . Non-small cell lung cancer in very young and very old patients. Chest. 2000; 117(2):354-7. DOI: 10.1378/chest.117.2.354. View

Zhu X, Zhang Z, Han G, Han J, Qiu D . Overexpression of miR‑214 promotes the progression of human osteosarcoma by regulating the Wnt/β‑catenin signaling pathway. Mol Med Rep. 2017; 15(4):1884-1892. DOI: 10.3892/mmr.2017.6203. View

10.

Carretero J, Medina P, Blanco R, Smit L, Tang M, Roncador G . Dysfunctional AMPK activity, signalling through mTOR and survival in response to energetic stress in LKB1-deficient lung cancer. Oncogene. 2006; 26(11):1616-25. DOI: 10.1038/sj.onc.1209951. View

11.

Du L, Zhao Z, Ma X, Hsiao T, Chen Y, Young E . miR-93-directed downregulation of DAB2 defines a novel oncogenic pathway in lung cancer. Oncogene. 2013; 33(34):4307-15. PMC: 4281941. DOI: 10.1038/onc.2013.381. View

12.

Inoue M, Okumura M, Sawabata N, Miyaoka E, Asamura H, Yoshino I . Clinicopathological characteristics and surgical results of lung cancer patients aged up to 50 years: the Japanese Lung Cancer Registry Study 2004. Lung Cancer. 2013; 83(2):246-51. DOI: 10.1016/j.lungcan.2013.11.007. View

13.

Sekine I, Nishiwaki Y, Yokose T, Nagai K, Suzuki K, Kodama T . Young lung cancer patients in Japan: different characteristics between the sexes. Ann Thorac Surg. 1999; 67(5):1451-5. DOI: 10.1016/s0003-4975(99)00171-x. View

14.

Wu Z, He B, He J, Mao X . Upregulation of miR-153 promotes cell proliferation via downregulation of the PTEN tumor suppressor gene in human prostate cancer. Prostate. 2012; 73(6):596-604. DOI: 10.1002/pros.22600. View

15.

Waggott D, Chu K, Yin S, Wouters B, Liu F, Boutros P . NanoStringNorm: an extensible R package for the pre-processing of NanoString mRNA and miRNA data. Bioinformatics. 2012; 28(11):1546-8. PMC: 3356845. DOI: 10.1093/bioinformatics/bts188. View

16.

Hou X, Du H, Quan X, Shi L, Zhang Q, Wu Y . Silibinin Inhibits NSCLC Metastasis by Targeting the EGFR/LOX Pathway. Front Pharmacol. 2018; 9:21. PMC: 5809401. DOI: 10.3389/fphar.2018.00021. View

17.

Inge L, Coon K, Smith M, Bremner R . Expression of LKB1 tumor suppressor in non-small cell lung cancer determines sensitivity to 2-deoxyglucose. J Thorac Cardiovasc Surg. 2009; 137(3):580-6. DOI: 10.1016/j.jtcvs.2008.11.029. View

18.

Rich A, Khakwani A, Free C, Tata L, Stanley R, Peake M . Non-small cell lung cancer in young adults: presentation and survival in the English National Lung Cancer Audit. QJM. 2015; 108(11):891-7. DOI: 10.1093/qjmed/hcv052. View

19.

Chen L, Engel B, Welsh E, Yoder S, Brantley S, Chen D . A Sensitive NanoString-Based Assay to Score STK11 (LKB1) Pathway Disruption in Lung Adenocarcinoma. J Thorac Oncol. 2016; 11(6):838-49. PMC: 4877210. DOI: 10.1016/j.jtho.2016.02.009. View

20.

Weiss J, Langer C . Treatment of lung cancer in the elderly patient. Semin Respir Crit Care Med. 2013; 34(6):802-9. DOI: 10.1055/s-0033-1358560. View